Solving the Unsolvable
Redefining drug discovery at the molecular level
By combining the technology and data engine of Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, we created the only end-to-end condensate drug discovery platform built on molecular insights.
Our differentiated molecular platform…
Through our one-of-a-kind technology, we unite droplet microfluidics and state-of-the art cellular imaging for novel drug discovery.
…delivers unique data…
We reveal the impact of chemical matter on condensate systems at the molecular level.
…and powers drug discovery.
Our pioneering engine optimizes chemical matter using machine learning and artificial intelligence.
Latest News
Transition Bio, Inc., a microfluidics- driven drug discovery platform company using biophysical…
Transition Bio, Inc. (the Company) today named several critical additions to its leadership team, including naming Gregory Miller as CEO…
Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined…
